Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Lymphoid 6Myeloid 5CNS 5Thoracic 4Sarcoma 3Other solid neoplasm 3Head & Neck 3Gynecologic 3Tumor-Agnostic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Hematuria 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Valproic Acid × Genitourinary × Clear all
NCT01738815 2021-10-22

Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

State University of New York - Upstate Medical University

Phase EARLY_PHASE1 Completed
43 enrolled
Genitourinary

Urinary Bladder Neoplasms, Hematuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡